199 related articles for article (PubMed ID: 38248101)
21. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.
Baba A; Goto TK; Ojiri H; Takagiwa M; Hiraga C; Okamura M; Hasegawa S; Okuyama Y; Ogino N; Yamauchi H; Kobashi Y; Yamazoe S; Munetomo Y; Mogami T; Nomura T
Dentomaxillofac Radiol; 2018 May; 47(4):20170323. PubMed ID: 29365278
[TBL] [Abstract][Full Text] [Related]
22. Primary wound closure after tooth extraction for prevention of medication-related osteonecrosis of the jaw in patients under denosumab.
Matsumoto A; Sasaki M; Schmelzeisen R; Oyama Y; Mori Y; Voss PJ
Clin Oral Investig; 2017 Jan; 21(1):127-134. PubMed ID: 26924135
[TBL] [Abstract][Full Text] [Related]
23. Antimicrobial peptide gene expression in medication-related osteonecrosis of the jaw.
Thiel Y; Ghayor C; Lindhorst D; Essig H; Weber F; Rücker M; Schumann P
Pathol Res Pract; 2020 Dec; 216(12):153245. PubMed ID: 33065485
[TBL] [Abstract][Full Text] [Related]
24. Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review.
Kawahara M; Kuroshima S; Sawase T
Int J Implant Dent; 2021 May; 7(1):47. PubMed ID: 33987769
[TBL] [Abstract][Full Text] [Related]
25. Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors.
van Cann T; Loyson T; Verbiest A; Clement PM; Bechter O; Willems L; Spriet I; Coropciuc R; Politis C; Vandeweyer RO; Schoenaers J; Debruyne PR; Dumez H; Berteloot P; Neven P; Nackaerts K; Woei-A-Jin FJSH; Punie K; Wildiers H; Beuselinck B
Support Care Cancer; 2018 Mar; 26(3):869-878. PubMed ID: 28963584
[TBL] [Abstract][Full Text] [Related]
26. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
Spring LM; Zangardi ML; Moy B; Bardia A
Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
[TBL] [Abstract][Full Text] [Related]
27. Differences between osteoradionecrosis and medication-related osteonecrosis of the jaw.
Akashi M; Wanifuchi S; Iwata E; Takeda D; Kusumoto J; Furudoi S; Komori T
Oral Maxillofac Surg; 2018 Mar; 22(1):59-63. PubMed ID: 29224060
[TBL] [Abstract][Full Text] [Related]
28. [Pharmacological Effects of CDK4 & 6 Selective Inhibitor Abemaciclib in Hormone Receptor-Positive Breast Cancer].
Tamaki C; Hayashi S; Sato A; Maeda K; Sakaguchi S; Buchanan S; Enatsu S
Gan To Kagaku Ryoho; 2019 Sep; 46(9):1405-1411. PubMed ID: 31530780
[TBL] [Abstract][Full Text] [Related]
29. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
Svejda B; Muschitz Ch; Gruber R; Brandtner Ch; Svejda Ch; Gasser RW; Santler G; Dimai HP
Wien Med Wochenschr; 2016 Feb; 166(1-2):68-74. PubMed ID: 26847441
[TBL] [Abstract][Full Text] [Related]
30. Selective Percutaneous Controlled Radiofrequency Thermocoagulation of the Gasserian Ganglion To Control Facial Pain Due to Medication-Related Osteonecrosis of the Jaw.
Taniguchi A; Fukazawa K; Hosokawa T
J Palliat Med; 2017 Oct; 20(10):1171-1174. PubMed ID: 28772087
[TBL] [Abstract][Full Text] [Related]
31. A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.
Chong QY; Kok ZH; Bui NL; Xiang X; Wong AL; Yong WP; Sethi G; Lobie PE; Wang L; Goh BC
Pharmacol Res; 2020 Jun; 156():104686. PubMed ID: 32068118
[TBL] [Abstract][Full Text] [Related]
32. Prognosis of medication-related osteonecrosis of the jaws in metastatic prostate cancer patients.
Wei LY; Kok SH; Lee YC; Chiu WY; Wang JJ; Cheng SJ; Chang HH; Lee JJ
Oral Dis; 2022 Jan; 28(1):182-192. PubMed ID: 33254278
[TBL] [Abstract][Full Text] [Related]
33. Denosumab-related osteonecrosis of the jaw following non-surgical periodontal therapy: A case report.
Diniz-Freitas M; Fernández-Feijoo J; Diz Dios P; Pousa X; Limeres J
J Clin Periodontol; 2018 May; 45(5):570-577. PubMed ID: 29479739
[TBL] [Abstract][Full Text] [Related]
34. Comparison of healthcare resource utilization and costs of patients with HR+/HER2- advanced breast cancer treated with ribociclib versus other CDK4/6 inhibitors.
Burne R; Balu S; Guérin A; Bungay R; Sin R; Paul ML
J Med Econ; 2021; 24(1):806-815. PubMed ID: 34098827
[TBL] [Abstract][Full Text] [Related]
35. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
Dodson TB
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367
[TBL] [Abstract][Full Text] [Related]
36. Medication-related osteonecrosis (MRONJ) of the mandible and maxilla.
Dunphy L; Salzano G; Gerber B; Graystone J
BMJ Case Rep; 2020 Jan; 13(1):. PubMed ID: 31907213
[TBL] [Abstract][Full Text] [Related]
37. Real-World Treatment Patterns and Clinical Outcomes among Patients Receiving CDK4/6 Inhibitors for Metastatic Breast Cancer in a Canadian Setting Using AI-Extracted Data.
Moulson R; Feugère G; Moreira-Lucas TS; Dequen F; Weiss J; Smith J; Brezden-Masley C
Curr Oncol; 2024 Apr; 31(4):2172-2184. PubMed ID: 38668064
[TBL] [Abstract][Full Text] [Related]
38. Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer.
Palumbo A; Lau G; Saraceni M
Ann Pharmacother; 2019 Feb; 53(2):178-185. PubMed ID: 30099886
[TBL] [Abstract][Full Text] [Related]
39. Absolute Lymphocyte Count Is an Independent Prognostic Factor for ER-positive HER2-negative Advanced Breast Cancer Patients Treated With CDK4/6 Inhibitors.
Kanaoka H; Nagahashi M; Atake Y; Hattori A; Bun A; Fukui R; Ozawa H; Fujimoto Y; Higuchi T; Natori K; Imamura M; Murase K; Takatsuka Y; Miyoshi Y
Anticancer Res; 2022 Oct; 42(10):4867-4878. PubMed ID: 36192009
[TBL] [Abstract][Full Text] [Related]
40. Consolidation of Tumorous Mandibular Ramus Defect During Denosumab Treatment for Rapidly Progressive Metastatic Breast Cancer.
Friedrich RE; Madani E
Anticancer Res; 2021 Oct; 41(10):5081-5087. PubMed ID: 34593458
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]